Neurotrophic factors for the treatment of Parkinson's disease
| dc.contributor.author | Sullivan, Aideen M. | |
| dc.contributor.author | Toulouse, André | |
| dc.date.accessioned | 2012-11-12T13:41:45Z | |
| dc.date.available | 2012-11-12T13:41:45Z | |
| dc.date.copyright | 2011 | |
| dc.date.issued | 2011-06 | |
| dc.date.updated | 2012-11-06T14:07:21Z | |
| dc.description.abstract | Parkinson's disease (PD) is a common neurodegenerative disorder caused by the progressive degeneration of the nigrostriatal dopaminergic pathway. The resulting loss of dopamine neurotransmission is responsible for the symptoms of the disease. Available treatments are initially successful in treating PD symptoms; however, their long-term use is associated with complications and they cannot stop the neurodegeneration. Current research aims at developing new therapies to halt/reverse the neurodegenerative process, rather than treating symptoms. Neurotrophic factors are proteins critical for maintenance and protection of neurones in the developing and adult brain. Several neurotrophic factors have been investigated for their protective effects on dopaminergic neurones. Here we review some of the most promising factors and provide an update on their status in clinical trials. | en |
| dc.description.status | Peer reviewed | en |
| dc.description.version | Submitted Version | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Sullivan A.M., Toulouse A.; (2011) 'Neurotrophic factors for the treatment of Parkinson's disease'. Cytokine & Growth Factor Reviews, 22 (3):157-165. doi: http://dx.doi.org/10.1016/j.cytogfr.2011.05.001 | en |
| dc.identifier.doi | 10.1016/j.cytogfr.2011.05.001 | |
| dc.identifier.endpage | 165 | en |
| dc.identifier.issued | 3 | en |
| dc.identifier.journaltitle | Cytokine & Growth Factor Reviews | en |
| dc.identifier.startpage | 157 | en |
| dc.identifier.uri | https://hdl.handle.net/10468/759 | |
| dc.identifier.volume | 22 | en |
| dc.language.iso | en | en |
| dc.publisher | Elsevier | en |
| dc.rights | Copyright © 2011, Elsevier. NOTICE: this is the author’s version of a work that was accepted for publication in Cytokine & Growth Factor Reviews. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Cytokine & Growth Factor Reviews, [22, June 2011] http://dx.doi.org/10.1016/j.cytogfr.2011.05.001 | en |
| dc.subject | Glial cell line-derived neurotrophic factor | en |
| dc.subject | Growth/differentiation factor 5 | en |
| dc.subject | Neurturin | en |
| dc.subject | Mesencephalic astrocyte-derived neurotrophic factor | en |
| dc.subject | Cerebral dopaminergic neurotrophic factor | en |
| dc.title | Neurotrophic factors for the treatment of Parkinson's disease | en |
| dc.type | Article (peer-reviewed) | en |
